Interim analysis from the ASSURE trial shows that seladelpar significantly improves liver stiffness in patients with primary biliary cholangitis (PBC). This finding supports the potential of seladelpar as a therapeutic option for this rare liver disease.

Recent research indicates that statins may reduce the risk of disease progression and mortality in non-cirrhotic patients with primary biliary cholangitis. This finding could influence treatment strategies for managing this rare liver disease.

A systematic review and meta-analysis evaluated the safety profile of elafibranor in patients with primary biliary cholangitis compared to placebo. The findings contribute to understanding the drug's safety in this rare liver disease.

The Scottish Medicines Consortium has accepted Livdelzi for the treatment of primary biliary cholangitis, enhancing treatment options for patients suffering from chronic itch associated with the disease. This decision marks a significant step in addressing the unmet needs of this patient population.

The CHMP has recommended Lynavoy for EU approval as the first IBAT inhibitor targeting cholestatic pruritus in primary biliary cholangitis (PBC). This marks a significant advancement in treatment options for patients suffering from this rare condition.